Publications by authors named "Zamzam Tikriti"
KRAS and EGFR inhibitors: a new step in the management of colorectal cancer.
Transl Gastroenterol Hepatol
September 2024
Article Synopsis
- Targeted therapies, including monoclonal antibodies and ADCs, have significantly improved DLBCL treatment over the past 20 years, starting with the approval of Rituximab.
- Chimeric antigen receptor T-cells are now a second-line option for DLBCL patients who do not respond to initial treatments, and Polatuzumab has been approved for high-risk patients as part of first-line therapy.
- Bispecific antibodies are a new class of drugs that target two different proteins simultaneously and have shown promise as third-line treatments, with ongoing research into their use in combination with traditional therapies, yielding encouraging results.
Human epidermal growth factor 2 (HER2)-positive breast cancer (BC) represents nearly 20% of all breast tumors. Historically, these patients had a high rate of relapse and dismal prognosis. The advent of HER2-targeting monoclonal antibodies such as trastuzumab followed by pertuzumab had improved the prognosis of HER2-positive metastatic BC.
View Article and Find Full Text PDF